Company name Surface Oncology, Inc.
Stock symbol SURF
Status Under Investigation

NEW YORK, August 26, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Surface Oncology, Inc. (NYSE: SURF) on behalf of Surface Oncology  investors.  Our investigation concerns whether Surface Oncology has violated the federal securities laws and/or engaged in other unlawful business practices.

Our investigation concerns potential violations of federal securities laws pursuant to the company’s April 2019 initial public offering (“IPO”). On April 19, 2018 Surface Oncology held its IPO, offering shares at $15.00. Since it’s IPO, Surface Oncology stock has plummeted, and currently trades at just $2.22, or less than 15% of it’s IPO price.

If you purchased or otherwise acquired Surface Oncology shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?

Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.